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Abstract
Ovarian cancer is the most lethal gynecologic malignancy and the five-year survival rate is only 35%
after diagnosis. Epithelial ovarian cancer is a highly metastatic disease characterized by widespread
peritoneal dissemination and ascites. The death incidences from ovarian cancer could be
significantly lowered by developing new methods for the early diagnosis and treatment of this fatal
disease. Several potential markers have been identified recently. However, mucins are the most
promising markers for ovarian cancer diagnosis. Mucins are large extracellular, heavily glycosylated
proteins and their aberrant expression has been implicated in the pathogenesis of a variety of
cancers, including ovarian cancer. This review will summarize known facts about the pathological
and molecular characteristics of ovarian cancer, the current status of ovarian cancer markers, as
well as general information about mucins, the putative role of mucins in the progression of ovarian
cancer and their potential use for the early diagnosis and treatment of this disease.
Ovarian Cancer
The life-time risk of having ovarian cancer is 1 in 70
women. This is the fifth leading cause of death for women
in developing countries [1,2]. According to epidemiologi-
cal studies, age is a common risk factor of ovarian cancer
because the ovaries of post-menopausal women become
smaller and folded. This folding results in deep cleft for-
mations and formation of smaller cysts lined with ovarian
surface epithelial (OSE) cells [3-6]. The other risk factors
are: nulliparity, family history, history of fertility drug use
and endocrine disorders. Multiparity, use of oral contra-
ceptives, pregnancy and lactation all are associated with
lower risk of ovarian cancer because of the decreased
number of ovulation cycles [6-10]. Molecular alterations
are also known to occur in ovarian cancer. These molecu-
lar alterations include mutation in the p53 gene which is
known to be involved in DNA damage repair. Mutation in
BRCA1 and BRCA2 has also been reported in ovarian
tumors [11-15]. Inactivation or downregulation of tumor
suppressor genes and amplification of oncogenes is also a
potential cause of ovarian cancer. In ovarian tumors, the
downregulation of OVCA1 and OVCA2 (tumor suppres-
sor genes present in normal ovary) is reported, while their
functions in normal ovary are not well known [11,16]. In
contrast, overexpression/amplification of certain onco-
genes like C-MYC, RAS, AKT, EGFR (ErbB1 or HER1),
HER2/neu (ErbB2), CSF1 C-MYC, etc., is also well known
in ovarian tumors [3-5,11,14,17-20].
Ovarian Cancer Staging and Histological Types
Phenotypically, the following types of epithelial ovarian
cancers (90%) are classified based on their expressed
properties related to the epithelium of the fallopian tube
(serous tumors), proliferative endometrium
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(endometroid), endocervix or colonic epithelium (muci-
nous tumors), gestational endometrium (clear cell carci-
noma), or the urinogenital tract (transitional or Brenner
tumors) (Table 1). The remaining 10% of ovarian tumors
are gonadal-stromal tumors (6%), germ cell tumors (3%)
and metastatic tumors (1%) [5] (Table 1). The histologi-
cal classification of ovarian tumors suggests four different
stages in ovarian cancer: stage I (tumors involve one or
both the ovaries, 5 year survival 60-90%), stage II (tumors
involve one or both ovaries with pelvic extension, 5 year
survival 37-66%), stage III (tumors involve one or both
ovaries with intraperitoneal metastasis outside the pelvis,
retroperitoneal nodes or both, 5 year survival 5-50%) and
stage IV (tumors involve one or both ovaries with distant
metastases, i.e. to lungs or liver, 5 year survival 0-17%)
[5,21] (Table 2). The majority (90%) of ovarian cancers
are epithelial ovarian carcinomas (EOC) which are
thought to arise from the ovarian surface epithelium
(OSE). OSE is the outermost mesothelial (peritoneal) lin-
ing and least component of the normal ovary, with no
unique feature or known major functions. In addition, the
early changes and minor anomalies remain undetected in
this tissue [3,5,20]. Due to the anatomic location and the
lack of early symptoms, it has become a difficult task to
differentiate normal OSE, metaplasia, benign epithelial
tumors and borderline tumors. Ovarian cancer can be
treated effectively if detected at an early stage; but unfor-
tunately, at the present time most of the ovarian tumors
are not diagnosed before an advanced stage (stage III and
IV) primarily due to the lack of reliable biomarkers of
early diagnosis. Since most ovarian cancers are of epithe-
lial nature and mucins are considered to be the hallmark
of epithelial cells, the expression profile of mucins may
serve as a potential diagnostic/prognostic and therapeutic
target. In this article, we have compiled available informa-
tion on the expression profile of different mucins in ovar-
ian tumors and their potential role in ovarian cancer
diagnosis and treatment.
Mucins
Being that 90% of ovarian cancers are of epithelial origin,
mucins may be attractive candidates for the detection of
early stage ovarian cancer [1,2,5]. Mucins, large extracellu-
lar proteins, are heavily glycosylated with oligosaccha-
rides and are generally known for providing protection to
the epithelial tissues under normal physiological condi-
tions [22-24]. Mucins are usually secreted by the epithelial
tissues which remain in contact with relatively harsh envi-
ronments such as airway epithelium, stomach epithelia,
epithelial lining of intestine and ductal epithelial tissue of
liver, pancreas, gall bladder, salivary gland, lachrymal
gland, etc. In these tissues, epithelial cells are exposed to a
variety of microorganisms, toxins, proteases, lipases, gly-
cosidases and diverse microenvironment fluctuations that
includes pH, ionic concentration, oxygenation, etc. [22-
25]. All mucins share general characteristics. For example,
they have repetitive domains of peptides rich in serine,
threonine, and proline in their backbone. Serine and thre-
onine are sites for O- and N-glycosylation. Presence of the
tandem repeat domain which varies in number, length
and O-glycosylation is the common structural feature of
all mucins [23,26-29]. Their general structure and bio-
chemical composition provides protection for the cell sur-
face and specific molecular structures regulate the local
microenvironment near the cell surface. In addition,
mucins also communicate the information of the external
environment to the epithelial cells via cellular signaling
through membrane-anchored mucins [22-24,29]. It
appears that mucins have the capability of serving as cell
surface receptors and sensors and conducting signals in
response to external stimuli for a variety of cellular
responses like cell proliferation, cell growth, differentia-
tion and apoptosis. These reports suggest that the aberrant
expression of mucins may be implicated in the develop-
ment and progression of ovarian cancer.
Type of Mucins
Currently, there are twenty known mucins which have
been placed in two categories: secreted mucins (gel form-
ing: MUC2 [30], MUC5AC [31], MUC5B [32], MUC6
[33], and non-gel forming: MUC7 [34] MUC8 [35] and
MUC11[36]), and membrane bound mucins (MUC1[26],
MUC3 [37], MUC4 [38], MUC9 [39], MUC10 [40],
MUC12 [36], MUC13 [41], MUC16 [42,43], MUC17
[44], MUC18 [45] and MUC20 [46]).
Table 1: Classification of ovarian tumors
Epithelial ovarian tumors (90%) Mostly 
diagnosed after the age of 50.
Germ cell neoplasm (3%) Mostly 
diagnosed under the age of 30
Gonado-stromal tumors (6%) No 
particular pattern with age
Serous Teratomas Granulosa cell tumors
Mucinous Mature cyst teratomas Thecomas
Endometroid Immature teratomas Fibrosarcomas
Clear cell Dysgerminomas Sertoli cell tumors
Transitional cell or Brenner tumors Yolk sac tumors
Embryonal carcinomas
Leydig cell tumors
Metastatic tumors: Ovaries may have tumors due to secondary metastatis of stomach, colon, pancreas, appendix, breast, and hematopoietic system.Journal of Ovarian Research 2009, 2:21 http://www.ovarianresearch.com/content/2/1/21
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Mucin Expression in Normal Ovary and 
Nonmalignant Ovarian Cell Lines
Goblet cells or glandular structures are not present in nor-
mal ovaries and, therefore, the normal ovarian tissues are
not expected to express secretory mucins. Ovarian surface
epithelium (OSE) expresses a mixed epithelo-mesenchy-
mal phenotype and is the only compartment known to
express mucins. MUC1 is the only well known mucin
which is expressed by the OSE at a detectable level [3,4].
Cultured nonmalignant ovarian epithelial cell lines also
express MUC1 (a membrane associated mucin) and
MUC5AC (a secreted mucin) [47].
Mucin Expression in Ovarian Tumors
The expression of mucin genes by ovarian epithelial cells
has not been studied in detail and only a few reports are
available to address this issue. Phenotypically, EOCs are
among the most variable tumors of any organ in that they
may express ovarian tumor cells structurally related to the
epithelium of different organs [4]. It has been shown that
malignant ovarian tumors often express more mucins
than benign and borderline ovarian tumors. Different
studies (Table 3) on the expression of mucins in ovarian
tumors have shown overexpression of MUC1, MUC2,
MUC3, MUC4, MUC5AC and MUC16 or CA125 [4,47-
51]. In agreement with these studies, we also observed
overexpression of MUC1, MUC4 and MUC16 in several
ovarian tumors [52] with no or an undetectable level of
MUC4 and MUC16 in normal ovarian tissues. In northern
blot analysis a higher expression of MUC3 and MUC4 was
reported in early stage ovarian tumor samples compared
to the late stage ovarian tumor samples and it was pro-
Table 2: Stage and Features of the Ovarian Tumors
Stage Features % 5 year Survival
Stage I Tumor growth is limited to the one or both the ovaries 60-90
Stage II Tumor growth in the one or both the ovaries with extension in the pelvis 37-66
Stage III Tumor growth involves one or both ovaries with extension and intraperitoneal metastasis extended to the bowel, 
to the lining of the abdominal cavity, or to the lymph nodes
5-50
Stage IV Tumor growth in one or both ovaries with distant metastases to other organs such as lungs liver or in the chest 0-17
Table 3: Comparative expression profile of mucins in different stages and histological types of ovarian cancer
Gene Normal Ovary Borderline
(Mucinous)
Low Stage (Stage 1-2) High Stage 
(Stage 3-4)
Detection method
MUC1 +/- ++ + to +++ (in all 
histological types i.e. C, 
M, E, S)
+ to +++ (in all 
histological types i.e. C, 
M, E, S)
ISH, NB, IHC [47-50]
MUC2 ND +++ +++ (all histological 
types, primarily in 
mucinous type)
+ to ++ ISH, NB, IHC [47-51]
MUC3 ND +++ (primarily in 
intestinal phenotype
+++ (E, M) - to + ISH, NB [47,48]
MUC4 - +++ 
(primarily in endocervical 
phenotype)
+++ 
(all types i.e. C, M, E, S)
- to ++ ISH, NB, IHC [47,48]
MUC5AC ND ++ (primarily in gastric 
surface cell or mucinous 
type)
++ (E, M, S) ++ ISH, NB, [47,48]
MUC5B ND ++ 
(Express primarily in 
endocervical phenotype)
++ (C, S) - to + ISH, NB [47,48]
MUC13 ND + +++ (S, M) ++ (S, M) OMA, TMA, IHC [53,97]
CA125/MUC16 - - (express in non-
mucinous borderline 
tumors
- to +++ 
(rarely express in 
mucinous tumors)
+ to +++ 
(rarely express in 
mucinous tumors)
IHC [76-79]
MUC17 - + - - [44,97]
Note: C, M, E, and S are abbreviated for clear cell, mucinous, endometroid and serous histological types of ovarian tumors, respectively.
ISH, in-situ hybridization; NB, northern blotting; IHC, immunohistochemistry, TMA, tissue microarray, OMA, oligonucleotide microarrayJournal of Ovarian Research 2009, 2:21 http://www.ovarianresearch.com/content/2/1/21
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posed that they provided a protective function in ovarian
cancer [47]. However, in our study we did not see this cor-
relation with MUC4 [52]. The overexpression of MUC1 in
various types and stages of ovarian tumor samples is
reported in several studies [47,49,50]. Recently, our labo-
ratory has identified aberrant expression of a novel mem-
brane anchored mucin, MUC13, in ovarian cancer. In this
study, MUC13 expression was undetectable in normal
and benign ovarian samples while 66% of epithelial ovar-
ian cancer samples showed a significantly higher MUC13
expression. MUC13 was predominantly localized on the
apical membrane and in the cytoplasm. Moreover,
MUC13 expression was significantly (p < 0.05) higher in
mucinous and Brenners type of samples compared to
other histological types of ovarian cancer samples and
adjacent normal ovary samples [53]. The expression pat-
tern of certain membrane bound mucins in ovarian
tumors is shown in Figure 1.
Pathological Roles of Mucins in Ovarian Cancer
The acquirement of an invasive phenotype is one of the
pivotal features of malignant ovarian cells. In order to
progress and metastasize, ovarian cancer cells must lose
cell contacts with neighboring cells, traverse the basement
membrane and migrate through stroma to reach blood
vessels or the lymphatic system. Mucins may be impli-
cated in the exfoliation, dissemination and invasion of
the ovarian cancer cells due to the highly glycosylated
extracellular domain, which may protrude up to 200-
2000 nm above the cell surface [54-56]. The overexpres-
sion of mucins can effectively interfere with the function
of cell adhesion molecules by steric blocking of the inter-
action of the cell surface molecules. MUC1 is known to
suppress cell aggression and cell adhesion properties by
interfering with the functions of E-cadherin and other cell
adhesion molecules in MUC1 overexpressing breast can-
cer cells [54-56]. In addition to this, mucins may also be
involved in the invasion of the basement membrane by
modulating cell-matrix attachment because of their dif-
fused and basal localization in tumor cells. Mucins may
also have an immunosuppressive effect by covering the
surface of tumor cells and enabling access to the immune
responsive cells [24,54-60]. The juxtamembrane domain
of the membrane-bound mucins is known to promote cell
proliferation by intercellular signaling mediated via one
of their two/three EGF-like domains [24,55-61]. Moreo-
ver, the cytoplasmic tail of mucins like MUC1 is known to
induce several cell signaling pathways, which promote the
cell growth and proliferation in a variety of cancer cells
[24,55-57,61-64]. Additionally, our recent study demon-
strates that exogenous MUC13 expression induced mor-
phological changes, including scattering of cells. These
changes were abrogated through c-jun NH2-terminal
kinase (JNK) chemical inhibitor (SP600125) or JNK2
siRNA. Moreover, a marked reduction in cell-cell adhe-
sion and significant (p < 0.05) increases in cell motility,
proliferation and tumorigenesis in a xenograft mouse
model system were observed upon exogenous MUC13
expression. These cellular characteristics were correlated
with up-regulation of HER2, p21-activated kinase1
(PAK1) and p38 protein expression [53]. Additionally,
recent studies have shown the role of MUC16/CA125 in
ovarian cancer metastasis. MUC16 mucin interacts with
the glycosylphosphatidylinositol anchored glycoprotein
mesothelin at high affinity and facilitates the peritoneal
metastasis of ovarian cancer cells [65,66]. Moreover,
MUC16/CA125 expression has been shown to inhibit the
cytotoxic responses of human natural killer (NK) cells and
downregulate CD16 activity in ovarian cancer cells. It has
also been shown that MUC16/CA125 selectively binds to
30-40% of CD16+ NK cells in EOC patients. These studies
suggest immunosuppressive properties of MUC16/CA125
[67]. These above mentioned findings demonstrate the
aberrant expression of mucins in ovarian cancer and show
that mucin expression may alter the cellular characteristics
of ovarian cancer cells and also imply a significant role of
mucins in the pathogenesis of ovarian cancer.
Expression of MUC1 (A), MUC13 (B) and MUC16/CA125 (C) trans-membrane mucins in ovarian tumors Figure 1
Expression of MUC1 (A), MUC13 (B) and MUC16/CA125 (C) trans-membrane mucins in ovarian tumors.
AB CJournal of Ovarian Research 2009, 2:21 http://www.ovarianresearch.com/content/2/1/21
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Mucins as Serum Marker of Ovarian Cancer
The structural characteristics of mucins suggest the pres-
ence of potential proteolytic cleavage sites in most mucin
genes and several are known to cleave at the cell surface.
Mucins, which are normally confined to the epithelial sur-
faces, become exposed to circulation and their overexpres-
sion may establish their potential as a tumor marker and/
or diseased condition. Mucins already have shown their
great potential as serum markers of ovarian and various
other tumors. Aberrant O-glycosylation of mucins is par-
ticularly prominent in epithelial cancers. This feature has
been termed "glycodynamics". These heterogeneously O-
glycosylated mucins aberrantly enter the bloodstream in
malignant conditions which provide diagnostic biomark-
ers for detection and monitoring of cancer. Although
mucins are rapidly degraded by glycan-recognizing
hepatic clearance receptors in the liver, small subsets of
carcinoma mucins remained unrecognized by clearance
systems. Thus, circulating cancer mucins used as clinical
diagnostic markers likely represent only the clearance-
resistant "tip of the iceberg" [68]. For example, O-glycans
on circulating MUC16 recognized by antibody CA125
provide for diagnosis and monitoring of ovarian cancers
[42]. CA125, an established serum marker of ovarian
tumors, has been recently identified as a member of a
mucin family and named MUC16 [42,43,69]. MUC16 is
a large, heavily glycosylated transmembrane mucin. Sev-
eral studies have shown the importance of CA125/
MUC16 in ovarian cancer diagnosis. In fact, an elevated
level of CA125/MUC16 is a gold standard non-invasive
test for ovarian cancer diagnosis [70,71]. A decrease in
CA125 can provide a surrogate marker to determine the
response to chemotherapeutic drug(s) during the treat-
ment procedure [72]. Moreover, antigens such as CA19-9,
CA50, and CA242 are also the serum markers of various
malignant conditions and are present on heavily glyco-
sylated, high molecular weight mucins [22,73,74]. In
breast cancers, serum MUC1 measured by CA15-3 is a
well established assay and has been shown to correlate
with the clinical course [75]. MUC1 and MUC4 are also
known to be overexpressed in ovarian tumors. Despite
having a great importance in ovarian cancer, CA125 does
not display an elevated serum level in over 50% of the
women with early stage tumors because this antigen is not
expressed in most early stage ovarian tumors [1,76-79].
Additionally, an elevated level of CA125 was observed in
some other (pancreatic, breast, liver, bladder and lung)
cancers, benign conditions (diverticulitis, uterine fibroids,
endometriosis, and ectopic pregnancy) and physiological
conditions (pregnancy and menstruation). Therefore, the
discovery of new serum tumor markers capable of com-
plementing CA125 may allow for the development of a
reliable test for the early stage diagnosis of ovarian cancer.
Our recent and some previous studies showed the overex-
pression of MUC4 in a majority of early stage ovarian
tumors and a combined panel of MUC1, MUC4 and
MUC16 dramatically increased the sensitivity of MUC16
staining test [52]. Additionally, a recent study suggests the
overexpression of MUC4 in ovarian carcinoma cells
present in peritoneal effusions [80]. Furthermore, our lab-
oratory has recently identified the aberrant expression of
a novel transmembrane mucin, MUC13, in ovarian tumor
samples compared to normal/benign ovarian tissue sam-
ples [53]. Like other membrane-associated mucins,
MUC4 and MUC13 also have a proteolytic cleavage site in
its structure which may allow the cleavage of the extracel-
lular part of MUC4 and MUC13 and their release in the
blood stream [29]. A similar process occurs in case of
MUC1 and MUC16. These data suggest that a combined
panel of different mucins may improve sensitivity and
accuracy of the currently used serum based diagnosis of
ovarian cancer. Further, aberrant mucin expression may
be immunogenic and may elicit a potent antibody
response. This antibody response may also serve as a dis-
ease indicator. A recent study demonstrated the presence
of MUC1 antibodies in blood plasma samples which was
inversely correlated with risk of ovarian cancer [81]. These
studies suggest that the aberrant expression of mucins
holds great promise to serve as a surrogate marker of ovar-
ian cancer and ovarian cancer prognosis.
Use of Mucins in Radioimmunodiagnosis (RID) 
and Radioimmunotherapy (RIT)
Monoclonal antibodies against mucins may have poten-
tial applications in improving the diagnosis and therapy
of ovarian tumors, although very few published studies
are available to address this issue, so far, and continued
investigations are certainly required. The much higher
expression of mucins (MUC1, MUC4, MUC5AC, MUC13
and MUC16) in ovarian tumors compared to the sur-
rounding normal tissues can be exploited for the purpose
of radioimmunodiagnosis (RID) and radioimmuno-
therapy (RIT). MUC1 monoclonal antibodies radiola-
beled with γ-emitting radioisotopes like 99mTC and 111In
have been successfully used for the radioimmunodiagno-
sis of various malignancies [82]. As an extension of this
technique, monoclonal antibodies to the mucins, radiola-
beled with β-emitting isotopes such as 67Cu, or 188Re, may
be employed for the irradiation of spreading tumor cells
(radioimmunotherapy) while sparing normal cells [82-
84]. At present, MUC1 and MUC16 are the best and only
characterized mucins and monoclonal antibodies against
MUC1 and MUC16 are under preclinical and clinical
investigations for ovarian cancer treatment (Table 4).
Therapeutic efficacy of anti-MUC1 MAb (HMFG1: anti-
human milk fat globules) radiolabeled with 90Y, 186Re and
131I was investigated in an OVCAR3 ovarian cancer
xenograft model. These radiopharmaceuticals signifi-
cantly improved survival in treated mice compared to
control mice. Similarly, radiolabeled MUC16 MAbs alsoJournal of Ovarian Research 2009, 2:21 http://www.ovarianresearch.com/content/2/1/21
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caused significant delay in animal death. MUC13 is
another potential mucin which is highly expressed on the
surface of ovarian cancer cells, indicating its potential as a
target for RID and RIT. An emerging concept in radioim-
munotherapy is nano-radioimmunotherapy (Nano-RIT).
In these studies radiolabeled antibodies are coupled with
drug loaded liposomes or nanoparticles. This approach
will overcome some of the major obstacles associated
with conventional strategies and will improve tumor
uptake and retention time of radioimmunoconjugates
[85,86]. The radioimmunoconjugates can be safely
administered via an intravenous route despite the fact they
are mouse monoclonal antibodies and capable of induc-
ing human anti-mouse antibody (HAMA) responses.
However, this problem can be minimized in the future by
using modern antibody engineering techniques [87].
Anti-Cancer Vaccines Based on Mucins
In recent years, projects associated with the development
of tumor vaccines have received considerable attention
(Table 4). A further possible approach involves the use of
mucins as a vaccine and target for immune responses
(Table 4) [88,89]. Three types of strategies can be
employed for vaccine development: antibody-based, anti-
gen-based and cell-based. As we mentioned earlier, certain
membrane anchored mucins which are over/aberrantly
expressed in ovarian cancer can be targeted for mono-
clonal antibody generation and anti-cancer vaccine devel-
opment. Antibody generated against a tumor antigen can
trigger potent antibody-dependent cellular cytotoxicity
and T-cell response. Additionally, monoclonal antibodies
can persuade anti-idiotypic antibodies that mimic the
epitopes in tumor antigens and can elicit a potent anti-
cancer response in patients. For an anti-cancer vaccine,
synthetic peptide or DNA that encodes for a tumor anti-
gen can be administered to the patient and over time the
patient will develop an immune response by activation of
cytotoxic T cells. In a cell-based vaccine approach, tumor
cells of the same patient (autologous) or a different
patient (allogeneic) or dendritic cells (activated by cancer
antigen) are administered to the cancer patient to stimu-
late the immune system. The induction of potential anti-
MUC responses may provide potential benefits in target-
ing tumors overexpressing mucin antigens. MUC1 has
been successfully used as a target for immuno-directed
therapies and as a marker of disease progression [88-90].
The efficacy of the immune response to mucins or mucin
peptides can be effectively augmented by conjugation of
immune adjuvant and/or carrier proteins like Bacille Cal-
mette-Guerin (BCG) and keyhole limpet hemocyanin
(KLH). A cognate of the MUC1 peptide conjugated with
KLH and Quillaja saponaria (QS-21) has entered into clin-
ical trials for prostate cancer [91,92]. The use of naked
DNA is another attractive and relatively simple approach
for vaccination studies. MUC1 cDNA has been used as a
cancer vaccine in mouse models and has been shown to
result in long-term growth suppression of tumors [93,94].
Additionally, dendritic cells pulsed with mucin derived
peptides were able to induce a potent cytotoxic T-cell
response and provide therapeutic benefits [95,96]. For
ovarian tumors, which are known to overexpress mucins,
this may be a potential treatment approach with a better
survival outcome.
Conclusions
The mucin gene family has considerable potential impor-
tance in the cell biology, diagnosis and treatment of ovar-
ian malignancies. Various studies have shown the
overexpression of MUC1, MUC2, MUC3, MUC4,
MUC5AC and MUC16 in a variety of ovarian tumors. In
Table 4: Some mucin-based and other emerging therapies for ovarian cancer treatment [88-94]
Antibody targeting Vaccines
Antibody-based Antigen-based Cell-based
Anti-HER2/neu antibody 
(Herceptin) [In use]
Idiotypic vaccination with anti-
MUC1 HMFG1MAb [Phase I trial]
MUC1 presenting Immunogens 
[Phase I]
Fusions of ovarian carcinoma cells 
and dendritic cells (DC) 
[Preclinical]
90Y-labelled anti-MUC1 HMFG1 
MAb [Phase 1]
Anti-CA-125 B43.13 MAb vaccine 
(OvaRex) [Phase IIb]
Peptides derived from a folate 
binding protein [Phase 1]
MUC1 RNA transfected dendritic 
cells [Preclinical]
131I-labelled OC125 MAb [Phase I/
II]
Anti-idiotypic antibody ACA-125 
vaccine [Phase I/II]
Synthetic Lewis (y)-protein 
conjugate vaccine [Phase 1]
Genetically engineered GM-CSF 
producing tumor cells
131I-labelled MOv8 chimeric MAb 
[Phase 1]
Her2/neu presenting peptides 
vaccines [Phase 1]
Her2/neu and MUC1 peptide 
pulsed dendritic cells [Pilot study]
Nano-RIT with CA125 and anti-
HER2 MAb [Under investigation]
Theratope STn-KLH cancer 
vaccine [Phase 1]
Dendritic cells pulsed with tumor-
lysateJournal of Ovarian Research 2009, 2:21 http://www.ovarianresearch.com/content/2/1/21
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particular, a combined panel of MUC4, MUC5AC, and
MUC16 may offer an effective and reliable diagnostic sys-
tem and target for the management of various histological
grades and types of ovarian cancer, although their biolog-
ical functions are not clearly defined. The development of
new molecular biology techniques will allow researchers
to determine the biological role of mucins in the process
of ovarian tumor progression and response to therapy.
The gene locus of the majority of mucin genes has been
identified and, therefore, may be a potential target for
future gene-based therapies, including immunoliposome
targeted techniques. The use of mucins as targets for radi-
oimmunodiagnosis and radioimmunotherapy is also
being explored and appears to be a potential approach for
the diagnosis and treatment of ovarian tumors which
overexpress mucins. The advancement in the area of anti-
body engineering techniques provides an opportunity to
produce single-chain, divalent, tetravalent and human-
ized antibody constructs from murine monoclonal anti-
bodies. These molecules will be significantly less
immunogenic to the human host than their intact mouse
Ig counterparts, and may allow repeated intravenous/
intraperitoneal administrations of targeting radioconju-
gated molecules, improved tumor tissue penetration due
to reduced physical size with a minimal or no risk of an
HAMA response. In the light of available information, we
conclude that switching of mucin genes occurs in ovarian
cancer, which can be utilized for the early diagnosis and
treatment of ovarian tumors.
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